Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Pimavanserin in Alzheimer's Disease Agitation.

Next Previous
X
Search
Trial Profile

Phase II Study of Pimavanserin in Alzheimer's Disease Agitation.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pimavanserin (Primary)
  • Indications Agitation
  • Focus Therapeutic Use
  • Acronyms SERENE
  • Sponsors Acadia Pharmaceuticals

    • Most Recent Events

    • 04 Oct 2017 According to a company media release, ACADIA announced that due to the potential overlap of clinical sites and study participants between its Phase III HARMONY dementia-related psychosis study and this trial of pimavanserin in Alzheimer's disease agitation, it has decided to discontinue enrollment of new patients in the SERENE study. Patients already enrolled will complete the study as planned.
    • 04 Oct 2017 Status changed from recruiting to discontinued, according to an Acadia Pharmaceuticals media release.
    • 12 Nov 2016 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top